Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease.

Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disorder, with a dramatic socioeconomic impact. The progress of AD is characterized by a severe loss in memory and cognition, leading to behavioral changing, depression and death. During the last decades, only a few anticholinergic drugs were launched in the market, mainly acetylcholinesterase inhibitors (AChEIs), with indications for the treatment of initial and moderate stages of AD. The search for new AChEIs, capable to overcome the limitations observed for rivastigmine and tacrine, led Sugimoto and co-workers to the discovery of donepezil. Besides its high potency, donepezil also exhibited high selectivity for AChE and a very low toxicity. In this review, we discuss the main structural and pharmacological attributes that have made donepezil the first choice medicine for AD, and a versatile structural model for the design of novel AChEIs, in spite of multipotent and multitarget-directed ligands. Many recent data from literature transdue great efforts worldwide to produce modifications in the donepezil structure that could result in new bioactive chemical entities with innovative structural pattern. Furthermore, multi-potent ligands have also been designed by molecular hybridization, affording rivastigmine-, tacrine- and huperzine-donepezil potent and selective AChEIs. In a more recent strategy, structural features of donepezil have been used as a model to design multitarget-directed ligands, aiming at the discovery of new effective drug candidates that could exhibit concomitant pharmacological activities as dual or multi- enzymatic inhibitors as genuine innovative therapeutic alternatives for the treatment of AD.

[1]  V. Andrisano,et al.  Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. , 2012, European journal of medicinal chemistry.

[2]  C. Pérez,et al.  Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. , 2013, European journal of medicinal chemistry.

[3]  Irene Bolea,et al.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.

[4]  Yongzhou Hu,et al.  Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[5]  Jacky C K Yeung,et al.  Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation. , 2011, Bioorganic & medicinal chemistry letters.

[6]  A J Hopfinger,et al.  The rationale for E2020 as a potent acetylcholinesterase inhibitor. , 1996, Bioorganic & medicinal chemistry.

[7]  R. Ji,et al.  Synthesis and acetylcholinesterase inhibitory activity of huperzine A-E2020 combined compound. , 1999, Bioorganic & medicinal chemistry letters.

[8]  Rogers Sl,et al.  Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. , 1998, British journal of clinical pharmacology.

[9]  C. Wermuth,et al.  Aminopyridazines as acetylcholinesterase inhibitors. , 1999, Journal of medicinal chemistry.

[10]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[11]  F. J. Luque,et al.  Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. , 2005, Bioorganic & medicinal chemistry.

[12]  Qiaojun He,et al.  2-Phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors: a study on the importance of modifications at the side chain on the activity. , 2008, Bioorganic & medicinal chemistry.

[13]  Wei Wang,et al.  Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. , 2009, Bioorganic & medicinal chemistry.

[14]  A. Cavalli,et al.  Design, synthesis, and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors. , 2009, European journal of medicinal chemistry.

[15]  A. Cavalli,et al.  Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil. , 2001, Journal of medicinal chemistry.

[16]  M. Beazely,et al.  Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. , 2012, Bioorganic & medicinal chemistry letters.

[17]  P. Szymański,et al.  Synthesis and Biological Activity of New Donepezil-Hydrazinonicotinamide Hybrids , 2013, Drug Research.

[18]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[19]  Flávia Pereira Dias Viegas,et al.  Doença de Alzheimer: Caracterização, Evolução e Implicações do Processo Neuroinflamatório , 2011 .

[20]  Xingshu Li,et al.  Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. , 2012, Bioorganic & medicinal chemistry letters.

[21]  H. Sugimoto,et al.  Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. , 1995, Journal of medicinal chemistry.

[22]  Silvia Gobbi,et al.  Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. , 2010, Bioorganic & medicinal chemistry.

[23]  J. Blake,et al.  Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase. , 1994, Journal of medicinal chemistry.

[24]  M. Abdollahi,et al.  Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives. , 2010, Bioorganic & medicinal chemistry.

[25]  V. Andrisano,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. , 2004, Journal of medicinal chemistry.

[26]  José Marco-Contelles,et al.  Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease , 2013, Medicinal research reviews.

[27]  Jerry Yang,et al.  Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors. , 2011, Bioorganic & medicinal chemistry.

[28]  A. Cavalli,et al.  Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. , 2005, Journal of medicinal chemistry.

[29]  C. Luo,et al.  Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. , 2004, Bioorganic & medicinal chemistry letters.

[30]  Jana Sopkova-de Oliveira Santos,et al.  Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil. , 2005, European journal of medicinal chemistry.

[31]  Irene Bolea,et al.  Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. , 2011, European journal of medicinal chemistry.